#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16610	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2059	800.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1418	1418	C	1014	C	932	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30374	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3575	847.3	0	.	n	.	0	T695C	SNP	695	695	T	1040	1040	C	950	C,T,G	882,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30374	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3575	847.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1682	1682	A	1003	A	930	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30374	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3575	847.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2316	2316	C	951	C,T	872,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30374	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3575	847.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2390	2390	A	966	A,G	903,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30374	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3575	847.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2942	2942	C	980	C	919	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2312	folP	852	852	100.0	folP.l15.c4.ctg.1	1449	158.6	1	SNP	p	R228S	1	.	.	682	684	AGC	979	981	AGC	218;218;220	A;G,A;C	202;199,1;201	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6102	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3517	172.7	1	SNP	p	S91F	0	.	.	271	273	TCC	568	570	TCC	180;183;184	T;C;C,A	172;177;176,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6102	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3517	172.7	1	SNP	p	D95N	0	.	.	283	285	GAC	580	582	GAC	183;181;180	G,C;A;C	178,1;175;174	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6102	gyrA	2751	2751	99.85	gyrA.l6.c30.ctg.1	3517	172.7	1	SNP	p	D95G	0	.	.	283	285	GAC	580	582	GAC	183;181;180	G,C;A;C	178,1;175;174	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	722	724	AAT	196;194;190	A;A;T,A	182;181;174,1	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	0	.	p	.	0	A86T	NONSYN	256	258	GCG	743	745	ACG	188;190;190	A;C;G	172;174;175	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	800	802	CAC	222;222;224	C,A;A;C	206,1;209;213	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	0	.	p	.	0	S183N	NONSYN	547	549	AGT	1034	1036	AAT	71;71;71	A;A;T	69;70;70	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	0	.	p	.	0	M197I	NONSYN	589	591	ATG	1076	1078	ATA	65;65;68	A;T;A	60;62;64	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1398	mtrR	633	633	97.47	mtrR.l15.c30.ctg.1	1486	93.9	1	SNP	p	G45D	0	.	.	133	135	GGC	620	622	GGC	235;235;231	G;G;C	216;216;215	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5954	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2962	200.3	1	SNP	p	D86N	0	.	.	256	258	GAC	603	605	GAC	258;256;254	G;A;C	243;237;238	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5954	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2962	200.3	1	SNP	p	S87R	0	.	.	259	261	AGT	606	608	AGT	254;253;254	A;G;T	237;233;234	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5954	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2962	200.3	1	SNP	p	S87W	0	.	.	259	261	AGT	606	608	AGT	254;253;254	A;G;T	237;233;234	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5954	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2962	200.3	1	SNP	p	S87I	0	.	.	259	261	AGT	606	608	AGT	254;253;254	A;G;T	237;233;234	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5954	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2962	200.3	1	SNP	p	S88P	0	.	.	262	264	TCC	609	611	TCC	254;253;251	T;C;C	234;233;230	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5042	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2689	187.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1627	1629	GGC	257;254;255	G;G;C	239;238;238	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1204	1206	GCA	255;257;254	G;C;A,T	240;241;240,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1207	1209	ATC	254;254;257	A;T;C	241;240;242	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1219	1221	GTG	249;247;250	G;T;G	236;232;235	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1219	1221	GTG	249;247;250	G;T;G	236;232;235	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1723	1725	ACC	233;234;235	A;C,T;C	214;218,1;221	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1777	1779	GCG	227;226;229	G;C,G;G	197;170,1;186	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1777	1779	GCG	227;226;229	G;C,G;G	197;170,1;186	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1900	1902	GGC	154;152;153	G;G;C	144;141;140	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1909	1911	GGC	149;146;145	G;G;C	139;136;131	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4404	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2279	192.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1927	1929	CCG	121;122;127	C,G,A;C,A,G;G	95,4,1;98,1,1;99	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6474	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3018	213.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2604	porA	1146	1146	99.83	porA.l15.c17.ctg.1	1873	137.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	454	454	C	186	C	167	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	0	.	p	.	0	I45V	NONSYN	133	135	ATT	441	443	GTT	280;284;285	G,T;T;T	267,1;265;267	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	0	.	p	.	0	I75V	NONSYN	223	225	ATT	531	533	GTT	294;291;294	G;T;T	268;256;270	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	0	.	p	.	0	S89T	NONSYN	265	267	AGC	573	575	ACC	280;277;277	A,C;C;C	235,1;244;249	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	0	.	p	.	0	I98V	NONSYN	292	294	ATC	600	602	GTC	285;286;286	G;T;C	246;248;249	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	1	SNP	p	G120K	1	.	.	358	360	AAG	666	668	AAG	257;257;258	A;A;G	235;240;237	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	1	SNP	p	N121D	0	.	.	361	363	AAC	669	671	AAC	258;259;258	A;A;C	239;239;241	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3100	porB1b	1038	1038	99.52	porB1b.l15.c4.ctg.1	1558	198.1	1	SNP	p	A121N	1	.	.	361	363	AAC	669	671	AAC	258;259;258	A;A;C	239;239;241	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11498	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4846	236.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2008	2010	AAT	271;268;273	A,C;A;T	248,2;247;251	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1274	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	888	141.6	1	SNP	p	V57M	1	.	.	169	171	ATG	423	425	ATG	264;263;263	A;T;G	244;244;243	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
